Aikewei's capacity utilization rate has dropped significantly: multiple family members hold shares; revenue from core products is under pressure due to volatility.

Renowned economist Song Qinghui told Gangwan Business Observer that, under a relatively concentrated equity structure, two main risks may arise. First, opinions of other small and medium-sized shareholders may be overlooked, thereby undermining the diversity and innovativeness of corporate decision-making. Second, the absence of effective checks and balances may allow major shareholders’ personal biases to lead to poor decisions, adversely affecting the company. Third, internal financial controls may become riskier, jeopardizing the company’s financial stability and overall operational development. When the controlling shareholder also serves in management, numerous drawbacks emerge: on one hand, managerial motivation may be suppressed; on the other, the controlling shareholder may abuse their dominant position to the detriment of other shareholders or the company itself. Aikewei's capacity utilization rate has dropped significantly: multiple family members hold shares; revenue from core products is under pressure due to volatility. By Liao Ziwen, Gangwan Business Observer Recently, Jiangsu Aikewei Technology Co., Ltd. (hereinafter referred to as “Aikewei”) filed its prospectus with the Beijing Stock Exchange, with Ping An Securities serving as the sponsor institution. The company primarily engages in the research, development, production, and sales of oxime-series fine chemical products. Aikewei’s current principal products include oxime-type silanes (methyltris(butylketoximo)silane and vinyltris(butylketoximo)silane), hydroxylamine salts (hydroxylamine sulfate and hydroxylamine hydrochloride), and basic oxime compounds (acetaldoxime and acetone oxime). According to the prospectus, during the reporting period, revenue and unit prices for one of Aikewei’s key products—oxime-type silanes—have declined; simultaneously, capacity utilization rates across multiple product categories have fallen substantially. Notably, the company also faces non-compliant internal financial controls, including loan refinancing via external customers and discrepancies between the parties making sales payments and those signing contracts or conducting actual transactions. 01 Revenue from Core Products Shows Volatility During the reporting period—2021 to 2023 and the first half of 2024—Aikewei recorded revenues of RMB 611 million, RMB 656 million, RMB 684 million, and RMB 426 million, respectively; net profits attributable to shareholders of the parent company amounted to RMB 164 million, RMB 131 million, RMB 141 million, and RMB 122 million, respectively. During the reporting period, Aikewei’s oxime-type silane products generated revenues of RMB 339 million, RMB 281 million, RMB 273 million, and RMB 130 million, respectively; basic oxime compound products generated revenues of RMB 67.68 million, RMB 135 million, RMB 193 million, and RMB 175 million, respectively. Aikewei attributes the declining revenue from oxime-type silanes primarily to a sharp price surge in 2021 triggered by production halts at peer companies following workplace safety incidents; as those peers resumed operations, intensified market competition drove oxime-type silane prices downward. Aikewei’s oxime-type silanes—including methyltris(butylketoximo)silane and vinyltris(butylketoximo)silane—are mainly used in construction sealants and industrial sealants. During the reporting period, unit selling prices for oxime-type silanes fluctuated. Aikewei notes that, although both output and sales volume of oxime-type silanes increased overall during the reporting period, intensifying market competition and fluctuations in raw material prices caused unit prices to decline overall—and this decline outpaced the growth in sales volume—resulting in an overall drop in oxime-type silane revenue.

Dimensional Fund Advisors’ Q1 2021 holdings: virtually no增持 (increases);减持 (reductions): TSMC, Baidu, Xiecheng, NetEase.

Hi everyone, I’m Jiangxin. Today, let’s take a look together at Dimensional Fund Advisors’ portfolio holdings as of the end of Q1 2021. Dimensional Fund Advisors currently holds $320.3 billion in market value, up from $276.9 billion previously. Its portfolio added 130 new positions and increased stakes in 1,209 stocks. Simultaneously, it reduced positions in 1,939 stocks and fully exited 64 positions. The top ten holdings account for 9.83% of total market value. Top five buys and sells in Q1: Dimensional Fund Advisors’ top ten holdings as of Q1 2021 are as follows: Among its China-related ADRs, Dimensional Fund Advisors executed the following key moves: New positions: KE Holdings (Beike) and Li Auto—both very small. Increases: Minimal increases, including a small increase in ZTO Express. Reductions: Taiwan Semiconductor Manufacturing Company (TSMC), Baidu, Xiecheng (Xiecheng Technology), and NetEase. Below is Dimensional Fund Advisors’ complete list of China-related ADR position changes: Finally, a quick note: What is a Form 13F?

Dimensional Fund Advisors Discloses 6% Stake in Ecovyst Inc

Jul 14, 2026

Dimensional Fund Advisors LP filed an amended Schedule 13G disclosing a 6.0% beneficial ownership stake in Ecovyst Inc, managing shares across various client investment funds.

Stock Titan

2026-04-04

Harbor Capital Advisors Inc. Boosts Stock Holdings in Ecovyst Inc. ($ECVT)

2026-06-17

Ecovyst Inc (ECVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

2026-07-14

Dimensional Fund Advisors Discloses 6% Stake in Ecovyst Inc

2026-07-25

Ecovyst Inc (ECVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

2026-11-07

Ecovyst Inc (ECVT) Q3 2026 Earnings Call Highlights: Raised Guidance and Accelerating Share Repurchases

Dimensional Fund Advisors Discloses 6% Stake in Ecovyst Inc

FAQ